Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Eye prosthesis – Intraocular lens
Reexamination Certificate
1999-04-01
2001-02-13
Prebilic, Paul B. (Department: 3738)
Prosthesis (i.e., artificial body members), parts thereof, or ai
Eye prosthesis
Intraocular lens
C623S006600, C623S926000
Reexamination Certificate
active
06187042
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to intraocular lenses. In particular, the present invention relates to intraocular lens coating compositions for reducing the risk of posterior capsule opacification.
BACKGROUND OF THE INVENTION
Foldable intraocular lens (“IOL”) materials can generally be divided into three categories: silicone materials, hydrogel materials, and non-hydrogel acrylic materials. Many materials in each category are known. See, for example, Foldable Intraocular Lenses, Ed. Martin et al., Slack Incorporated, Thorofare, N.J. (1993). Biocompatibility varies among different IOL materials within and among each category.
One measure of biocompatability for an IOL can be the incidence of posterior capsule opacification (“PCO”). A number or factors may be involved in causing and/or controlling PCO. For example, the design and edge sharpness of an IOL may be a factor. See, Nagamoto et al., J. Cataract Refract. Surg., 23:866-872 (1997); and Nagata et al., Jpn. J. Ophthalmol., 40:397-403 (1996). See, also, U.S. Pat. Nos. 5,549,670 and 5,693,094. Another factor appears to be the lens material itself. See, for example, Mandle, “Acrylic lenses cause less posterior capsule opacification than PMMA, silicone IOLs,” Ocular Surgery News, Vol. 14. No. 15, p.23 (1996). See, also, Oshika, et al., “Two Year Clinical Study of a Soft Acrylic Intraocular Lens,” J. Cataract. Refract. Surg., 22:104-109 (1996); and Ursell et al., “Relationship Between Intraocular Lens Biomaterials and Posterior Capsule Opacification,” J. Cataract Refract. Surg., 24:352-360 (1998).
One method of addressing the PCO problem involves administering a pharmaceutical agent to the capsular bag area at the time of, or immediately after, extracapsular cataract extraction. See, for example, U.S. Pat. Nos. 5,576,345 (pharmaceutical agent=the cytotoxic agent taxol or an ophthalmically acceptable derivative); 4,515,794; and 5,370,687. Alternatively, the pharmaceutical agent may be tethered to the surface of the IOL material. See, for example, U.S. Pat. No. 4,918,165. The pharmaceutical agents are intended to kill or prevent the growth of proliferating cells that might cause PCO or “secondary cataracts.” Yet another method involves the physical destruction or removal of lens epithelial cells. See, Saika et al., J. Cataract Refract. Surg., 23:1528-1531 (1997).
Another method of addressing PCO is the prophylactic laser therapy method disclosed in U.S. Pat. No. 5,733,276. According to this method, the lens capsule is irradiated with laser irradiation to destroy cells which remain in the lens capsule after extraction of a cataract.
Other methods theorized for reducing the risk of PCO involve adhering the posterior capsule to the IOL at the time of implantation, as in U.S. Pat. No. 5,002,571. According to the '571 patent, a non-biological glue or, preferably, a biological glue, such as fibrin, collagen, or mussel glue, is used to adhere the posterior lens capsule to the posterior surface of an IOL. The glue may be applied over the entire posterior surface of the IOL or just as an annulus around the outer perimeter of the posterior surface of the IOL.
In contrast, U.S. Pat. No. 5,375,611 discloses a method of reducing the risk of PCO by preventing the adherence of the posterior capsule to the IOL. According to the '611 patent, the posterior surface of the lens capsule itself is chemically modified at the time of extracapsular cataract extraction. The chemical modification is achieved by depositing a water-insoluble stable or permanent layer of a cell attachment preventing compound onto the posterior surface of the lens capsule. The stable or permanent layer may be a polymer, such as olyethylene glycol, polysaccharides, polyethylenepropylene gylcol, and polyvinyl lcohols.
What is needed is a method of making lOLs made of materials having relatively high PCO rates more biocompatible by reducing the risk of PCO.
SUMMARY OF THE INVENTION
The present invention relates to IOL coating compositions for making IOL materials more biocompatible. More specifically, the present invention relates to a coated intraocular lens comprising a substrate material and a coating material for making the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coating material is different than the substrate material and the coating material consists essentially of at least two aryl acrylic hydrophobic monomers.
The present invention also relates to a method for reducing the risk of PCO. The method comprises implanting an IOL containing a posterior surface coating consisting essentially of at least two aryl acrylic hydrophobic monomers.
The present invention also relates to a method of applying coating compositions comprising at least two aryl acrylic hydrophobic monomers to an IOL. The method of applying the coating comprises the steps of polymerizing the coating material to form an uncross-linked polymer, dissolving the uncross-linked polymerized material to form a coating solution, applying the coating solution to the IOL, and securing the coating to the IOL's surface.
REFERENCES:
patent: 4515794 (1985-05-01), Emery et al.
patent: 4725276 (1988-02-01), Bissonette et al.
patent: 4846833 (1989-07-01), Cumming
patent: 4918165 (1990-04-01), Soll et al.
patent: 4950290 (1990-08-01), Kamerling
patent: 5002571 (1991-03-01), O'Donnell, Jr. et al.
patent: 5057578 (1991-10-01), Spinelli
patent: 5078740 (1992-01-01), Walman
patent: 5290892 (1994-03-01), Namdaran et al.
patent: 5331073 (1994-07-01), Weinschenk, III et al.
patent: 5359021 (1994-10-01), Weinschenk, III et al.
patent: 5366501 (1994-11-01), Langerman
patent: 5370687 (1994-12-01), Poler
patent: 5371147 (1994-12-01), Spinelli et al.
patent: 5375611 (1994-12-01), Lindqvist et al.
patent: 5405385 (1995-04-01), Heimke et al.
patent: 5470932 (1995-11-01), Jinkerson
patent: 5494946 (1996-02-01), Christ et al.
patent: 5549670 (1996-08-01), Young et al.
patent: 5576345 (1996-11-01), Mansson et al.
patent: 5593438 (1997-01-01), Akhavi et al.
patent: 5618316 (1997-04-01), Hoffman et al.
patent: 5693094 (1997-12-01), Young et al.
patent: 5693095 (1997-12-01), Freeman et al.
patent: 5733276 (1998-03-01), Belkin
patent: 5869549 (1999-02-01), Christ et al.
patent: 5876438 (1999-03-01), Kelleher et al.
patent: 5891931 (1999-04-01), Leboeuf et al.
patent: 6027531 (2000-02-01), Tassignon
patent: 0 559 820 B1 (1993-09-01), None
patent: 0 611 379 B1 (1996-05-01), None
patent: 0 781 777 A1 (1997-07-01), None
patent: 0 675 910 B1 (1997-09-01), None
patent: 0 904 747 A2 (1999-03-01), None
patent: 0 916 320 A2 (1999-05-01), None
patent: WO 94/11764 (1994-05-01), None
patent: WO 96/25962 (1996-08-01), None
patent: WO 96/34629 (1996-11-01), None
patent: WO 97/20851 (1997-06-01), None
patent: WO 98/15238 (1998-04-01), None
patent: 99/62435 (1999-12-01), None
Cunanan et al., “An In Vitro Test Method to Study Posterior Capsular Opacification,”Investigative Ophthalmology&Visual Science,vol. 38(4), p. S178 (1997).
Gabriel et al., “In Vitro Adherence ofPseudomonas aeruginosato Four Intraocular Lenses,”J. Cataract Refractive Surg,vol. 24, pp. 124-129 (1998).
Hollick et al., “Lens Epithelial Cells Regression on the Posterior Capsule: A 2 Year Prospective, Randomised Trial With Three Different IOL Materials,”Investigative Ophthalmology&Visual Science,vol. 38(4), p. S19 (1997).
Linnola et al., “Acrylate Intraocular Lenses (IOLs) Hinder Posterior Migration of Epithelium; Activity Tested by Corneal Tissue Cultures,”ESCRS Abstracts,p. 120 (1997).
Linnola, “Sandwich Theory: Bioactivity-based Explanation for Posterior Capsule Opacification,”J. Cataract Refract. Surg.,vol. 23, pp. 1539-1542 (1997).
Mandle, “Acrylic Lenses Cause Less Posterior Capsule Opacification than PMMA, Silicone IOLs,”Ocular Surgery News,vol. 14(15), p. 23 (1996).
Nagamoto et al., “Effect of Intraocular Lens Design on Migration of Lens Epithelial Cells Onto the Posterior Capsule,”J. Cataract Refract Surg.,vol. 23, pp. 866-872 (1997).
Nagata et al., “Adhesiveness of AcrySof to a Co
Karakelle Mutlu
LeBoeuf Albert R.
Patel Anilbhai S.
Sheets, Jr. John W.
Van Noy Stephen J.
Alcon Laboratories Inc.
Prebilic Paul B.
Ryan Patrick M.
LandOfFree
Intraocular lens coating compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intraocular lens coating compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intraocular lens coating compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2610539